Covid-19 News: Latest Covid-19 News, Indian Covid-19 News & Updates

While the efficacy of ZyCoV-D was 67% compared to mRNA vaccines and others, which is about 90%, there have been no late-stage studies that Zydus Cadila has promised to publish at a later date.

The vaccine ZyCoV-D received an Emergency Use Authorization (EUA) from the drug regulator on Aug. 20, making it the first vaccine to be administered in the 12-18 age group, alongside adults.

Pediatricians and experts have shared concerns about the availability and affordability of pediatric vaccines at a time when the central government and Zydus Cadila are also negotiating pricing for the DNA-based needle-free COVID-19 vaccine ZyCoV-D.

Zydus Cadila has been informed that he has proposed ₹1,900 for a three-dose ZyCoV-D shot. Zydus Cadila’s ZyCov-D – the world’s first plasmid DNA vaccine for Covid-19 is the only vaccine currently approved by the Drug Controller General of India (DCGI) for emergency use in children 12 years and older.

While the efficacy of ZyCoV-D was 67% compared to mRNA vaccines and others, which is about 90%, there have been no late-stage studies that Zydus Cadila has promised to publish at a later date. The vaccine works by prompting the immune system to produce spike proteins similar to the virus, which trigger the production of antibodies against the virus. This is a painless vaccine that is injected into the skin and subcutaneous tissue with a maximum concentration of macrophages that take up the DNA material and carry it to the cell nucleus.

Talking about the ZyCoV-D Covid vaccine, Dr. Santosh Soans, Past President, Indian Academy of Pediatrics (IAP) and Scientific Chair 2023, International Pediatric Association (IPA): “The concern is that efficacy is only 67% so far and requires further trials and we don’t know what the long-term ramifications will be. of the new technology, such as the risk of gene change. There is a chance of continued antibody production, resulting in an unknown inflammatory disease.”

Every new product launched in the market will have a higher cost because of the research involved. The Zydus Cadila vaccine also requires a jet applicator and needs three doses compared to other Covid vaccines, but during the pandemic we need to support the government initiative for a universal vaccine for every man, woman and child and reduce the cost to less than 1500 which I think is appropriate.”

“Children under the age of 18 make up a significant part of the population, 472 million people, who stayed indoors for more than a year, mostly unaffected by the virus and without a vaccine. However, according to Indian Council of Medical Research (ICMR) data from a national serosurvey, 65 percent of them had antibodies. In addition, because they have fewer ACE-2 receptors in their lungs, they may be less sensitive. Despite this, more than 100 children died each week from COVID-19 in Indonesia in July, challenging the widely held belief that children are at low risk for COVID-19,” said Ahmedabad-based pharmaceutical consultant Dr. Sanjay Agrawal.

Zydus Cadila COVID-19 Vaccine ZyCoV-D will soon be introduced in the nationwide anti-coronavirus vaccination campaign, according to official sources.

Center is also awaiting recommendations from the National Technical Advisory Group on Immunization (NTAGI) for introducing ZyCoV-D into the immunization campaign and for prioritizing beneficiaries targeting individuals ages 12-18 with co-morbidities.

The vaccine ZyCoV-D received an Emergency Use Authorization (EUA) from the drug regulator on Aug. 20, making it the first vaccine to be administered in the 12-18 age group, alongside adults.

Clinical trials are underway for Covovax, a Covid-19 vaccine developed by US company Novavax Inc. for children under 18 by the Serum Institute of India (SII). Clinical trials for the biological E protein subunit vaccine Corbevax, in children ages 5 to 18 and older, are also underway, and it is expected to be rolled out in December this year, according to official sources.

Get live stock quotes from BSE, NSE, US market and latest NAV, portfolio of mutual funds, watch the latest IPO news, top performing IPOs, calculate your tax through income tax calculator, know the market’s top wins, top losers and best stock funds . Like us on Facebook and follow us on Twitter.

Comments are closed.